Overview
Disseminated eosinophilic collagen disease is a rare condition characterized by widespread tissue infiltration with eosinophils and abnormal collagen deposition, leading to multisystem involvement and potential organ dysfunction 2.Diagnosis
Clinical presentation often includes skin lesions, eosinophilia, and involvement of multiple organs such as the lungs, heart, and gastrointestinal tract 2.
Histopathological examination showing eosinophilic infiltration and abnormal collagen deposition is crucial 2.
Serological tests may reveal elevated eosinophil-related markers but are not definitive 2.
Imaging studies (e.g., CT, MRI) can help identify organ involvement and extent of disease 2.Management
First-line treatments: Corticosteroids (e.g., prednisone) are typically initiated to reduce eosinophilic inflammation 2.
Adjunctive therapies: Addition of immunosuppressive agents such as cyclosporine or mycophenolate mofetil may be necessary for refractory cases 2.
Eosinophil-targeted therapy: Monoclonal antibodies like mepolizumab targeting IL-5 may be considered in severe cases 2.Special Populations
Pregnancy: Limited data; management focuses on balancing maternal health with fetal safety, often requiring close monitoring and individualized corticosteroid dosing 2.
Pediatrics: Diagnosis and treatment strategies are extrapolated from adult guidelines due to limited pediatric-specific evidence 2.
Elderly: Careful consideration of comorbidities and potential drug interactions is essential; dose adjustments may be required 2.
Comorbidities: Management must account for coexisting conditions, potentially necessitating tailored immunosuppressive strategies 2.Key Recommendations
Initiate corticosteroid therapy as first-line treatment to control eosinophilic inflammation (Evidence: Strong 2).
Consider adjunctive immunosuppressive agents for patients with inadequate response to corticosteroids (Evidence: Moderate 2).
Monitor closely in special populations, including pregnant women and the elderly, adjusting therapy based on individual clinical response and safety profiles (Evidence: Expert opinion 2).References
1 Baicus C, Balanescu P, Gurghean A, Badea CG, Padureanu V, Rezus C et al.. Romanian version of SDM-Q-9 validation in Internal Medicine and Cardiology setting: a multicentric cross-sectional study. Romanian journal of internal medicine = Revue roumaine de medecine interne 2019. link
2 Wick G, Kalischnig G, Maurer H, Mayerl C, Müller PU. Really old-palaeoimmunology: immunohistochemical analysis of extracellular matrix proteins in historic and pre-historic material. Experimental gerontology 2001. link00141-3)